

*Barcelona, Spain*

Annual Congress of the  
European Association of Nuclear Medicine

October 12 – 16, 2019  
Barcelona, Spain

## **Joint Symposium 28**

Translational and Molecular Imaging Therapy + Oncology Committee / World Molecular Imaging Society (WMIS)

**Wednesday, October 16, 10:00-11:30**

### **Session Title**

**Translational Aspects of PSMA Targeting**

### **Chairpersons**

Margaret Schottelius (Garching, Germany)

Matthias Eiber (Munich, Germany)

### **Programme**

10:00 - 10:30 Jan Grimm (New York, United States of America / WMIS): Biology of PSMA

10:30 - 11:00 Martin G. Pomper (Baltimore, United States of America): Update on PSMA Tracers

11:00 - 11:30 Frederik Lars Giesel (Heidelberg, Germany): Clinical Relevance PSMA Targeting

### **Educational Objectives**

1. Improve understanding of the PSMA biology
2. Provide the in's and out's of PSMA specific tracer design
3. Understanding of the clinical impact created by PSMA targeting strategies

### **Summary**

In this joint symposium with the world molecular imaging society, we focus on one of the recent success stories of molecular imaging/nuclear medicine, namely precision medicine strategies that are based targeting of the prostate specific membrane antigen (PSMA). To educate the audience on the potential and impact of this target, three complementary lectures will be provided. By starting with the biology of PSMA e.g expression levels and mechanisms behind over expression, the biomedical relevance of the target will be underscored. This will be followed by an update on innovations in PSMA tracer chemistry that have allowed targeting of the receptor with a high sensitivity and specificity – both for diagnostics and therapy. To complete the translational circle, the final lecture will address the clinical impact of PSMA targeting strategies. Together, this will provide a true ‘from bench to bedside’ overview of this valuable theranostic target.

### **Key Words**

Prostate cancer, PSMA, molecular imaging, urology